The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

BMS, Clovis form collaboration to evaluate Opdivo and Rubraca

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Bristol-Myers Squibb Co. and Clovis Oncology Inc. formed a clinical collaboration to evaluate the combination of BMS’s Opdivo and Clovis Oncology’s poly (ADP-ribose) polymerase inhibitor Rubraca in pivotal phase III clinical trials in:

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account